Figure 4.

Melatonin promotes PLC/IP3/Ca²⁺ pathway activation. PHZ-induced neonatal hemolytic hyperbilirubinemia significantly decreased (A) PLC activity, (B) IP3 content, (C) CaMKIV phosphorylation, and (D) CREB phosphorylation. Melatonin therapy partially rescued (A) PLC activity, (B) IP3 content, (C) CaMKIV phosphorylation, and (D) CREB phosphorylation. Pre-treatment with the PLC inhibitor U73122 abolished effects of melatonin on (A) PLC activity, (B) IP3 content, (C) CaMKIV phosphorylation, and (D) CREB phosphorylation. All experiments were performed in triplicate. Data are reported as means ± standard errors of the mean (SEMs). * p<0.05 vs. control group; ^# p<0.05 vs. PHZ group; ^$ p<0.05 vs. PHZ + melatonin group.